TABLE 2.

Ongoing BBB Disruption Clinical Trials in Glioma Patients

Study title	ClinicalTrials.gov identifier	Study location(s)	Intervention	Condition	Status
Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9 (SC9-GBM-01)	NCT03744026	Hôpital Neurologique Pierre Wertheimer, Bron, France	SonoCloud-9 (CarThera, Paris, France)	GBM	Recruiting
ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy	NCT03712293	Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea	ExAblate Model 4000 Type 2.0 (Insightec Tirat Carmel, Israel)	GBM	Recruiting
Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients	NCT03626896	Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan	NaviFUS System (NaviFUS, Taiwan)	GBM, brain tumor	Completed
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma	NCT03616860	Sunnybrook Health Sciences Centre, Toronto, Canada	ExAblate (Insightec Tirat Carmel, Israel)	GBM	Recruiting
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors	NCT01473485	Sunnybrook Health Sciences Centre, Toronto, Canada	ExAblate Transcranial System (Insightec Tirat Carmel, Israel)	Gliomas, metastatic brain cancer	Recruiting
ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma	NCT03322813	University of Maryland Medical System, Baltimore, Maryland	ExAblate 4000 Type 2 (Insightec Tirat Carmel, Israel)	Glioma	Recruiting
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma	NCT03551249	Brigham Women's Hospital and University of Maryland, Baltimore, Maryland	ExAblate (Insightec Tirat Carmel, Israel)	GBM	Recruiting